Inventor and Co-Founder of Wi-LAN, Inc. Brings His Unique Combination of Pioneering Work, Research and Entrepreneurship to Canadian Biomedical Technology Company Focused on Obesity and Diabetes
VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 19, 2015) - M Pharmaceutical Inc., (CSE:MQ)(OTCQB:MPHMF), (the "Company") a Canadian company committed to developing and commercializing innovative biomedical technologies that improve the health and quality of life for people affected by obesity and diabetes, has named Dr. Michel Fattouche, a professor in the Department of Electrical and Computer Engineering at the University of Calgary, to the company's Advisory Board.
Dr. Fattouche, a registered Professional Engineer in the Province of Alberta, Canada, is a former "Calgarian of the Year" (2000) and "Prairies Entrepreneur of the Year" (2000) in Communications and Technology by Ernst and Young.
"Given the vision of the Company as a leader in biomedical products reliant on innovative technologies, it only adds to our strength by having somebody of Dr. Michel Fattouche's stature as one of our chief advisors," said Dr. Martin Mintchev, President & Chief Executive Officer of M Pharmaceutical, Inc. "We're very pleased to have Dr. Fattouche on our Advisory Board. His expertise and scope of knowledge in the field of electrical engineering and wireless communications will help us greatly as we move toward the final development and launch of technologies such as the e-Mosquito, gastro-intestinal neurostimulators and temporary controllable pseudobezoars."
The research work attributed to Dr. Fattouche has led to 21 patents being issued and 14 filed, including his pioneering work and patents in W-OFDM (Wide-band Orthogonal Frequency Division Multiplexing). That work led to his co-founding of the trail-blazing Wi-LAN Inc. in 1993. Wi-LAN's patented W-OFDM technology is being incorporated into the "WiMAX" Standard 802.16 developed by the Institute of Electrical and Electronics Engineers (IEEE).
Based on his related patents on Super-Resolution, Dr. Fattouche also co-founded Cell-Loc Inc. in 1995. Eight years later in 2003, Cell-Loc Inc. became Cell-Loc Location Technologies Inc., the developer of a family of network-based wireless location products that enable location-sensitive services.
The work of Dr. Fattouche has been widely cited internationally and he is viewed as a transformative leader in his field. He was named "Professor of the Year" by the Student Union for Teaching Excellence in the Department of Electrical and Computer Engineering at the University of Calgary in 1999.
"We welcome Dr. Fattouche to the M Pharmaceutical, Inc. Advisory Board that also includes research and technology leaders such as Dr. Douglas Janzen and Dr. Orly Yadid-Pecht," added Dr. Mintchev. "We're gratified to be able to rely on their expertise as we move forward in the development of the eMosquito, gastrointestinal neuro-stimulators and temporary controllable pseudobezoars."
About M Pharmaceutical Inc.
M Pharmaceutical Inc. is committed to developing and commercializing innovative biomedical technologies that improve the health and quality of life of people affected by obesity and diabetes. The Company currently has or has agreed to acquire the exclusive rights to a family of biomedical technologies including (i) the eMosquito, for automatic and autonomous monitoring of blood glucose by diabetics; (ii) temporary controllable pseudobezoars, an innovative method for non-invasive dynamic gastric volume reduction for weight loss that has been recently tested in blind, placebo-controlled human studies; and (iii) gastrointestinal neurostimulators, using a laparoscopically-implantable technique for the treatment of obesity without permanent anatomical modification of the stomach. Commercial development of eMosquito, Trimeo and Trimtec biomedical technologies will require successful coordination and execution of a wide variety of technology disciplines.
Forward Looking Statements:
This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to the eMosquito, Trimeo and Trimtec biomedical technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and such factors as the Company failing to complete the commercialization of the eMosquito, Trimeo and Trimtec biomedical technologies.